Safety of pembrolizumab for resected stage III melanoma.

Published in: Expert opinion on drug safety (2020)

Pembrolizumab as adjuvant therapy of resected stage III melanoma showed an acceptable safety profile, which is comparable to that in advanced melanoma. However, it caused one death. There is uncertainty about its benefits in AJCC-8 stage IIIA melanoma patients. Additionally, caution is required since OS and long-term safety data are not available yet.

Keyphrases

skin cancer
prognostic factors
end stage renal disease
lymph node
ejection fraction
advanced non small cell lung cancer
chronic kidney disease
basal cell carcinoma
big data
artificial intelligence
tyrosine kinase